Pfizer-BioNTech vaccine deliveries could start 'before Christmas'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/5/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- S&P Dow Jones Indices adds Bloom Energy to S&P 500 index
- Citi highlights best Gen AI stocks to own for 2027
- Dell’s earning report was bullish for Intel CPU demand, analyst says
- Netflix raises prices in Germany and Austria, Citi comments
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Wells Fargo Reiterates Overweight Rating on Johnson & Johnson (JNJ)
November 19, 2020 6:46 AM ESTWells Fargo analyst Larry Biegelsen reiterated an Overweight rating and $172.00 price target on Johnson & Johnson (NYSE: JNJ) following the company's virtual booth tour, ahead of its analyst day.
On its Q3 call, JNJ indicated that it expected Q4 MD recovery to continue with... More
Pfizer (PFE), BioNTech (BNTX) Confirm Phase 3 Study of COVID-19 Vaccine Candidate Shows 95% Efficacy
November 18, 2020 7:00 AM ESTPfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that, after conducting the final efficacy analysis in their ongoing Phase 3 study, their mRNA-based COVID-19 vaccine candidate, BNT162b2, met all of the studys primary efficacy endpoints. Analysis of the data indicates a vaccine efficacy rate of 95% (p... More
